Capistol

CyDex is dedicated to the development and commercialization of specialty pharmaceutical products. The company is in the process of conducting preclinical and clinical studies on a promising pipeline of oral, parenteral and inhaled drug candidates designed to address unmet needs in asthma, depression, allergy, cancer, arrhythmia and other disease states. Lead products in clinical development include Budesonide Inhalation Solution for asthma, Sertraline Oral Solution for depression, Fexofenadine Oral Liquid for allergic rhinitis and Propofol Solution for anesthesia. CyDex s lead technology, Captisol, is a modified cyclodextrin that improves the solubility, stability and bioavailability of a number of drug compounds. CyDex also partners worldwide with pharmaceutical and biotechnology companies, such as Pfizer, which markets two Captisol-enabled parenteral formulations, Vfend and Zeldox. Founded in 1993, CyDex is headquartered in Lenexa, Kan.